Gamma-hydroxybutyrate Oral Composition Fed State Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for narcolepsy, such as Xyrem®, require patients to take the first dose at least 2 hours after eating due to significant food-induced reduction in bioavailability, leading to reduced patient compliance, efficacy, and safety, as well as increased risk of abuse.
Innovation Solution
Development of an oral pharmaceutical composition containing gamma-hydroxybutyrate in a unit dose suitable for administration less than two hours after eating, which maintains bioequivalence to an immediate release liquid solution of sodium oxybate administered at least two hours after eating, providing improved pharmacokinetic properties in the fed state.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If gamma-hydroxybutyrate is administered in the fed state (less than 2 hours after eating), then patient compliance and convenience are improved, but bioavailability is significantly reduced
Solution Approach 1:
The patent modifies the physical and chemical parameters of gamma-hydroxybutyrate by converting it to salt forms (sodium, potassium, lithium, ammonium salts) and implementing specific pH control mechanisms. This allows the drug to maintain stable absorption characteristics across different fed states, resolving the contradiction between ease of administration and bioavailability
Solution Approach 2:
The patent introduces pH-adjusting agents and buffering systems as intermediaries to control the gastrointestinal environment. These intermediaries maintain optimal pH conditions for gamma-hydroxybutyrate absorption even in the presence of food, thereby preserving bioavailability while allowing flexible dosing timing
2Adaptability or versatility
If gamma-hydroxybutyrate is administered in the fed state, then dosing flexibility is improved, but absorption consistency deteriorates
Solution Approach 1:
The patent employs pH-modifying excipients and buffering systems to stabilize the chemical environment in the gastrointestinal tract. This ensures that gamma-hydroxybutyrate maintains consistent absorption characteristics regardless of variations in feeding conditions or dosing timing, thereby preserving absorption consistency while enabling dosing flexibility
3Speed
If immediate release liquid solution is used, then rapid onset of action is achieved, but food effect on absorption is significant
Solution Approach 1:
The patent creates composite formulations by combining gamma-hydroxybutyrate salts with pH-adjusting agents, buffering systems, and specialized excipients. This composite approach maintains the rapid onset characteristics of immediate release formulations while protecting against food-induced bioavailability reduction through controlled pH environments
Data Source
AI summary
Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.